Current Report Filing (8-k)
June 25 2019 - 12:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 21, 2019
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
333-192759
|
20-3373669
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer No.)
|
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices
and Zip Code)
877 424-2429
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
None
|
N/A
|
N/A
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 – DEPARTURE OF DIRECTORS
OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On June 21
st
, 2019, the Board
of Directors of the Corporation nominated two Independent Directors to its Board. The Independent Directors shall each be compensated
with 125,000 Warrants, at a strike price of $.30. Said Warrants shall have a one-year life.
Dr. Estery Giloz-Ran, 45,
has
held the position of
visiting Scholar at the Stern School of Business at New York University,
Visiting
Professor in the School of Business at the Yeshiva University, former Head of Accountancy at the Peres Academic Center’s
School of Business, and is currently a Lecturer at the Bar Ilan University in Israel, Department of Economics and Accounting. Dr.
Giloz-Ran is an External Director in several public companies including Blue Square Real Estate, Aran R&D, Oversiz, Suny, Kamada
and is the Former Chairperson of the Board of Tamir Fishman, a known venture capital fund. Dr. Giloz-Ran
is a licensed CPA,
holds an MBA in Business Administration from Ben Gurion University, and a PhD in Tax, Accounting & Finance from Ben Gurion
University
Eran Ballan
54,
brings executive management experience with large public entities in international markets. Mr. Ballan served as Partner, and Head
of the Biotech Department at Naschitz Brandeis, one of the largest law firms in Israel
.
Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv public company part of the
TA-35 and Real-Estate 15 index in Israel.
Mr. Ballan holds an LL. B
degree from Essex University,
UK, and an LL.M degree from New York University Faculty of Law.
Item 9.01 – FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
The following Exhibits are filed as part of this
Current Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: June 25, 2019
|
CANNABICS PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Eyal Barad
|
|
Name:
|
Eyal Barad
|
|
Title:
|
Chief Executive Officer
|
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Feb 2024 to Mar 2024
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Mar 2023 to Mar 2024